Shares of Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.03 and traded as high as $0.03. Mateon Therapeutics shares last traded at $0.03, with a volume of 43,156 shares.
Mateon Therapeutics Price Performance
The firm has a 50-day moving average of $0.04 and a 200 day moving average of $0.03.
About Mateon Therapeutics
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Further Reading
- Five stocks we like better than Mateon Therapeutics
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Power Play: Japan’s Top Auto Stocks Eye Historic Merger
- Where to Find Earnings Call Transcripts
- S&P 500 Earnings Set to Shine: January’s Critical Market Test
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
